Skip to main content
Premium Trial:

Request an Annual Quote

Agilent SureSelect Clinical Research Exome V2

Agilent Technologies has introduced a new target enrichment technology for next-generation sequencing. The SureSelect Clinical Research Exome V2 adds coverage for 1,099 additional disease-relevant targets, 75,000 splice sites of noncoding exons, more than 12,000 deep intronic variants, and more than 800 variants in promoter regions. The targets were curated in collaboration with Emory University and the Children's Hospital of Philadelphia.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.